An Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IVB103 Injection in Subjects with Neovascular (wet) Agerelated Macular Degeneration (nAMD)
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs IVB 103 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors InnoVec Biotherapeutics
- 25 Dec 2024 New trial record